Dr. Christopher Cheng, GST’s President/CEO is responsible for sustainment, growth, and delivery of services to GST’s diverse customer base.
Chris has 20+ years of experience as a leader in industry and academia. In his industry experience, he has managed teams within startups to blue chip medical device companies, with experience spanning research, design, manufacturing, preclinical testing, clinical trials, marketing, and fundraising. Chris was co-founder and CEO of Koli, Inc., a Silicon Valley startup developing a minimally-invasive, percutaneous solution for symptomatic gallstone disease. Most recently, he founded GST’s Medical Division, the first organization dedicated to helping medical device companies holistically evaluate and improve biomechanical compatibility of medical implants. Chris has helped companies achieve clinical trial and commercial approval for dozens of products in the US and internationally, and is a seasoned speaker and subject matter expert.
In academia, Chris is the preeminent expert in vascular motion, with over 100 publications and author of Handbook of Vascular Motion (PROSE Book Award Nominee, https://www.elsevier.com/books/handbook-of-vascular-motion/cheng/978-0-12-815713-8, the only book devoted to how blood vessels move. He is also an Adjunct Professor in the Division of Vascular Surgery at Stanford, Director of the Vascular Intervention Biomechanics & Engineering (VIBE) lab (, and President of Cardiovascular Implant Durability Inc. (cvidconference.org), a non-profit organization leading the effort to improve durability of medical devices.
Chris received his B.S.E. in Biomedical Engineering and Electrical Engineering from Duke University, M.S. and Ph.D. degrees in Mechanical Engineering from Stanford University, and currently serves on the board of the Duke University Pratt School of Engineering.